We have determined that EZH2 inhibitors can suppress prostate cancer lineage plasticity, neuroendocrine transformation, and resistance to androgen receptor targeted therapies in pre-clinical mouse and human experimental models (Ku et al., 2017). The gene discussed is EZH2; the disease is prostate carcinoma.